



**Consolidated Financial Statements for the Year Ended March 31, 2019**  
**FY2019 (April 1, 2018 - March 31, 2019) [UNAUDITED]**

May 14, 2019

|   |   |
|---|---|
| Company name:   | Takara Bio Inc.   |
| Stock exchange listings:                                | Tokyo Stock Exchange (1st section)                                    |
| Code number:  | 4974  |
| URL:  | <a href="http://www.takara-bio.co.jp">http://www.takara-bio.co.jp</a> |
| Company representative:                                 | Koichi Nakao, President   |
| Contact:  | Shuichiro Matsuzaki, Executive Vice President<br>Tel. (077) 565-6970  |
| Scheduled date of general shareholders' meeting:        | June 21, 2019   |
| Scheduled date of starting delivery of dividends:       | June 24, 2019   |
| Scheduled date of annual securities report filing date: | June 27, 2019   |
| Supplementary documents of the financial results:       | Yes   |
| Financial results information meeting:                  | Yes   |

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.  
 2. Amounts are rounded down to the nearest million yen.

**1. Results for the year ended March 31, 2019 (Apr. 1, 2018 – Mar. 31, 2019)**

**(1) Consolidated operating results**

|  | (Percentages indicate changes from the same period of the previous fiscal year.) |          |                          |       |
|--|--|----------|--------------------------|-------|
|  | Year ended Mar. 31, 2019   |          | Year ended Mar. 31, 2018 |       |
|  | (Millions of yen)  | (%)      | (Millions of yen)        | (%)   |
| Net sales  | 35,841   | 10.9     | 32,312                   | 10.0  |
| Operating income                                       | 5,463  | 53.7     | 3,555                    | 11.0  |
| Ordinary income  | 5,665  | 46.7     | 3,861                    | 7.9   |
| Net income (loss) attributable to owners of the parent | 3,657  | 56.6     | 2,335                    | 72.6  |
| Net income per share (in yen)                          | 30.38  |          | 19.39                    |       |
| Fully diluted net income per share (in yen)            | -  |          | -                        |       |
| Return on equity                                       |  | 5.8%     |                          | 3.8%  |
| Ordinary income to total assets ratio                  |  | 8.1%     |                          | 5.7%  |
| Operating income to net sales ratio                    |  | 15.2%    |                          | 11.0% |
| Note: Comprehensive income                             | 2,705  | (10.2 %) | 2,455                    | (- %) |

**(2) Consolidated financial position**

|                               | As of Mar. 31, 2019 | As of Mar. 31, 2018 |
|-------------------------------|---------------------|---------------------|
|                               | (Millions of yen)   | (Millions of yen)   |
| Total assets                  | 71,040              | 68,670              |
| Net assets                    | 64,095              | 61,959              |
| Equity ratio (%)              | 90.1                | 90.1                |
| Net assets per share (in yen) | 531.57              | 513.66              |
| (Reference) Equity            | 64,009              | 61,852              |

Note: Partial revision of accounting standard related to tax effect accounting (Article 28 on corporate accounting standard, February 16, 2018) has been applied from the beginning of the year ended March 31, 2019. Accordingly, financial position for the year ended March 31, 2018 indicates the numerical value after retroactive adjustment due to this revision.

**(3) Consolidated cash flow**

|                                     | Year ended Mar. 31, 2019 | Year ended Mar. 31, 2018 |
|-------------------------------------|--------------------------|--------------------------|
|                                     | (Millions of yen)        | (Millions of yen)        |
| Cash flow from operating activities | 5,783                    | 3,935                    |
| Cash flow from investing activities | (5,576)                  | (14,755)                 |
| Cash flow from financing activities | (541)                    | (1,205)                  |
| Cash and cash equivalents, end year | 9,464                    | 10,051                   |

The original disclosure in Japanese was released on May 14, 2019 at 15:00 (GMT+8)

## 2. Dividends

|                                  | Annual dividends per share in yen |                             |   |
|----------------------------------|-----------------------------------|-----------------------------|---|
|                                  | Year ended Mar. 31,<br>2018       | Year ended Mar. 31,<br>2019 | Year ending Mar. 31,<br>2020 (Forecast) |
| First quarter end                | -                                 | -                           | -                                       |
| Second quarter end               | 0.00                              | 0.00                        | 0.00                                    |
| Third quarter end                | -                                 | -                           | -                                       |
| Year end                         | 4.50                              | 7.00                        | 8.00                                    |
| Annual                           | 4.50                              | 7.00                        | 8.00                                    |
| Total dividend (Millions of yen) | 541                               | 842                         | -                                       |
| Payout ratio (%)                 | 23.2                              | 23.0                        | 22.7                                    |
| Dividend on equity (%)           | 0.9                               | 1.3                         | -                                       |

## 3. Forecast for the year ending March 31, 2020 (Apr. 1, 2019 – Mar. 31, 2020)

(Percentages indicated changes from the same period of the previous fiscal year.)

|  | Six months ending Sep. 30, 2019 |       | Year ending Mar. 31, 2020 |      |
|--|---------------------------------|-------|---------------------------|------|
|  | (Millions of yen)               | (%)   | (Millions of yen)         | (%)  |
| Net sales  | 17,129                          | (1.4) | 36,000                    | 0.4  |
| Operating income                                   | 2,917                           | 11.2  | 6,200                     | 13.5 |
| Ordinary income                                    | 3,001                           | 12.4  | 6,450                     | 13.9 |
| Net income attributable to<br>owners of the parent | 1,950                           | 13.3  | 4,250                     | 16.2 |
| Net income per share (in yen)                      | 16.20                           |       | 35.29                     |      |

## ※ Others

### (1) Changes in subsidiaries during the period

(Changes in specified subsidiaries resulting in change of scope) : No

Newly included: - (Name)

Excluded: - (Name)

### (2) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard: No

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

### (3) Number of outstanding shares (Common stock)

#### 1) Number of outstanding shares at year end (Treasury stocks are included)

As of March 31, 2019 120,415,600

As of March 31, 2018 120,415,600

#### 2) Number of treasury stocks at year end

As of March 31, 2019 -

As of March 31, 2018 -

#### 3) Average number of outstanding shares

As of March 31, 2019 120,415,600

As of March 31, 2018 120,415,600

※ These financial statements are not subject to auditing.

※ Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Company based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Overview of Financial Results (4) Future Outlook, on page 3 of the attached document.

The Company will hold a briefing for institutional investors and analysts on May 16, 2019. The material handed out at this briefing and a review of questions and answers will be posted on our website.

(Change in calendar indication)

Calendar indication has been changed from Japanese style to western style since Consolidated Financial Statements for the first quarter ended June 30, 2018.